OBJECTIVES: Despite recent progress in diagnostic technology and therapeutic approaches to non-small-cell lung cancer (NSCLC), 30-75% of patients develop tumour recurrence after resection. However, the details of post-recurrence survival (PRS) are not well understood. We aimed to investigate the predictors of PRS in patients with NSCLC initially completely resected.
INTRODUCTION
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related deaths around the world, especially in developed countries [1] . Surgery is one of the major therapeutic choices for treating primary lung cancer and the prognosis, if the patients with NSCLC underwent curative resection, has improved during the last decade [2, 3] . However, 30-75% of patients develop tumour recurrence depending on the pathological stage despite initial complete resection for NSCLC [2, 4] . We have considerable experience with long-surviving cases after recurrence; however, most recurrent cases have poor outcomes.
At this time, post-recurrence survival (PRS) is not well understood, especially in recent years. There are likely many factors related to PRS such as varied patient background and standard treatment strategy. To date, no prospective study has been done to establish relationships of factors like these to PRS.
The progresses in the management of NSCLC such as diagnostic imaging, chemotherapy including molecular-targeting drugs, establishment of appropriate adjuvant chemotherapy and highprecision radiotherapy have contributed to the improvement of outcome of patients with advanced NSCLC. These advances likely have major impacts on PRS. The aim of our study was to examine the prognostic predictors of PRS in patients with NSCLC initially completely resected.
PATIENTS AND METHODS
A total of 568 consecutive patients, who had undergone curativeintent complete resection for NSCLC at Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital during the period from January 2000 to December 2009, formed the initial study cohort.
Institutional Review Board-approved informed consent was obtained from all of them.
All clinicopathological data were retrieved from medical records. All patients had a solitary lesion at the time of primary surgery and patients with other cancers were excluded from the current analysis. Preoperative evaluation included a physical examination, blood cell count and chemistry analysis, measurement of serum tumour markers, bronchoscopy, chest radiograph, computed tomography (CT), brain magnetic resonance imaging (MRI) or CT and bone scintigraphy. Since 2003, integrated positron emission tomography scan and CT scan (PET/CT) have also been performed in principle. The serum carcinoembryonic antigen (CEA) level was measured by means of the enzyme immunoassay method, with the ADVIA Centaur® XP analyser (Siemens, Munich, Germany). According to the manufacturer's instructions, the cut-off point for serum CEA 5.0 ng/ml was used in the current analysis. All patients underwent a lobectomy, bilobectomy or pneumonectomy and systematic lymph node dissection for resection of the primary lesion. Complete resection was defined as complete removal of all tumours with negative margin proven by surgical findings and histopathological examination.
All the surgical specimens underwent pathological examination. Each tumour was diagnosed according to the current World Health Organization's histological classification [5] and was staged according to the seventh edition of tumour node metastasis classification of the International Union Against Cancer [6] . Vascular invasion, pleural invasion and lymphatic permeation were evaluated using both haematoxylin and eosin-stained and Victoria blue van Gieson-stained sections.
Based on our postoperative follow-up policy, we examined patients at 3-month intervals for the first 3 years and typically at 6-month intervals thereafter on an outpatient basis, and aimed at continuing follow-up for 10 years after surgery. The routine follow-up evaluation included physical examination, chest radiography, chest CT and blood examination including serum tumour markers. In particular, chest and abdomen CT was regularly performed at 6-month interval. Whenever any symptoms or signs of recurrence were detected, further evaluation was performed, including CT of the chest and abdomen, brain MRI and bone scintigraphy or PET/CT. Recurrent lesions were diagnosed through physical examination and diagnostic imaging of lesions was consistent with recurrent lung cancer. Histological or cytological confirmation of the diagnosis was made when clinically feasible. If it was not feasible, radiological evidence of recurrent lesion was accepted. The criteria proposed by Martini and Melamed [7] were utilized for differentiating second primary lung cancer from intrapulmonary metastasis. The final decisions on diagnosis of recurrent NSCLC, treatment plan and assessment of chemotherapeutic effects were made by the institutional multidisciplinary board of lung cancer. Patients were included in the PRS analysis only when specific data were available for the exact anatomical site of recurrence as well as any treatment given during the follow-up period.
We also evaluated the initially observed recurrence pattern. During the initial recurrence period, a classification of locoregional recurrence was made if lesions detected were limited within the ipsilateral lung, ipsilateral hilar and mediastinal lymph nodes. Single recurrence focus involving adjacent anatomical sites was not considered a multisite recurrence unless each site was treated separately, and the initial site of recurrence was classified as the single site most extensively involved with the recurrent tumour.
The following clinicopathological characteristics were retrieved from available medical records: age, gender, smoking history, tumour differentiation, pathological stage, serum CEA level, serum albumin, histological type, pathological stage, pleural invasion, vascular invasion, lymphatic permeation, epidermal growth factor receptor (EGFR) mutation, surgical procedure, disease-free interval (DFI), number of recurrent foci, recurrent site and postrecurrence treatment.
Receiver-operating characteristics (ROC) curve for each continuous variable was generated for identification of the optimal cut-off value, and we defined it as the closest point to the upper left-hand corner on the curve. Disease-free interval was measured in months from the date of initial surgery to the date of initial detection of recurrent disease or last follow-up without evidence of recurrence. PRS was defined as the time in days from the date of initial detection of recurrent disease to the date of death from any cause or the last date the patient was known to be alive. Patients known to be alive at last follow-up were censored. PRS curves were plotted using the Kaplan-Meier method and survival differences in variables were determined using the log-rank test. Cox proportional hazards regression models were used with multivariate analysis to determine which variable demonstrated the strongest associations with PRS. A forward step-wise selection procedure was implemented with a P-value threshold of 0.05 for inclusion in the final model. All tests were two-sided, and P-values less than 0.05 were considered statistically significant. The statistical analysis was performed using the SPSS software (version 20; SPSS, Inc., Chicago, IL, USA).
RESULTS
The initial study cohort included 568 consecutive patients with completely resected NSCLC, and median follow-up time was 73 months (range: 1-176 months). Their clinicopathological characteristics are given in Table 1 . It included 314 (55.3%) male and 254 (44.7%) female patients, with a mean age of 68 years (range: 19-88 years). Of the 568 patients, 397 (69.9%) had adenocarcinoma, 121 (21.3%) had squamous cell carcinoma, 27 (4.9%) had large cell carcinoma and 23 (4.0%) had others (7 large cell neuroendocrine carcinoma, 7 adenosquamous carcinoma, 5 carcinoid and 4 pleomorphic carcinoma). Of the 568 patients, 138 (24.3%) were identified as having recurrent disease during the study follow-up period. Median disease-free interval was 21 months (range: 3-119 months) and median age at recurrence was 71 years (range: 24-85 years). The 2-and 5-year PRS rates were 44.6 and 25.9%, respectively, and median PRS time was 22.5 months (95% CI: 19.4-25.6 months, Fig. 1A ) .
The 138 patients with recurrent disease included 86 (62.3%) male and 52 (37.7%) female patients, with a median age of 68 years (range: 19-88 years). Of the 138 patients, 79 (57.2%) had adenocarcinoma, 45 (32.6%) had squamous cell carcinoma, 6 (4.3%) had large cell carcinoma and 8 had others (4 large cell neuroendocrine carcinoma, 2 adenosquamous carcinoma and 2 pleomorphic carcinoma). Initially observed recurrence site was loco-regional in 75 (54.3%), lung in 89 (64.5%), bone in 15 (10.9%), brain in 16 (11.6%) and liver in 2 (1.4%). EGFR mutation status was wild type in 73 (52.9%), mutated in 33 (23.9%) and unknown in 32 (23.2%) and 35 (25.4%) patients received epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) and no patients received anaplastic lymphoma kinase inhibitor.
Receiver-operating characteristics curve was used to test the predictive ability of age at recurrence, pathological stage and DFI for the cancer-specific death. Age at recurrence of 65 years corresponded to the maximum joint sensitivity of 87.2% and specificity of 38.6% on the ROC plot. We thus set the age at recurrence of 65 years as cut-off value for prognostic analysis. In the same way, pathological stage II (sensitivity: 34.0%, specificity: 68.2%) and DFI of 12 months (sensitivity: 75.5%, specificity: 38.2%) are also identified as cut-off value with the closest point to the upper left-hand corner on the ROC plot.
Univariate and multivariate prognostic analysis for overall survival in the original cohort Supplementary Table 1 shows 5-year overall survival and univariate/multivariate analyses according to clinicopathological characteristics of patients with NSCLC initially completely resected in original cohort. Univariate analysis identified the following seven significant prognostic factors: male gender, non-adenocarcinoma histology, poor differentiation, pathological stage II or III, lymphatic permeation, vascular invasion, pleural invasion and serum CEA ≥5.0 mg/dl at initial surgery. Multivariate Cox regression analysis demonstrated that pathological stage II or III [hazard ratio (HR) = 2.643, 95% confidence interval (CI): 1.861-3.753, P < 0.001], vascular invasion (HR = 1.819, 95% CI: 1.223-2.684, P = 0.003), pleural invasion (HR = 1.563, 95% CI: 1.095-2.232, P = 0.014) and serum CEA ≥5.0 mg/dl (HR = 1.928, 95% CI: 1.376-2.703, P < 0.001) were independent predictors of overall survival.
Univariate prognostic analysis for post-recurrence survival Table 2 shows 2-year PRS rates of each group and univariate analysis according to clinicopathological characteristics of patients and primary lung cancer using Kaplan-Meier methods and logrank test. The clinically significant predictors of PRS, included five factors: gender (male vs female, P = 0.007), age at recurrence (<65 vs ≥65 years, P = 0.015), histological type (adenocarcinoma vs others, P < 0.001), tumour differentiation (well or moderate vs poor, P = 0.029) and serum CEA at recurrence (<5.0 vs ≥5.0 mg/dl, P = 0.002). Table 3 also shows 2-year PRS rates for each group and univariate analysis according to both characteristics of recurrent disease and post-recurrence treatment. Univariate analysis demonstrated that systemic chemotherapy (excluding EGFR-TKI, P < 0.001) and EGFR-TKI (P = 0.008) were significant predictors of PRS.
Multivariate Cox regression analysis for post-recurrence survival
We performed a multivariate Cox regression analysis to determine which variable was an independent predictor of PRS. The seven clinicopathological characteristics and post-recurrence treatment factors that were shown to be significant prognostic factors of PRS by univariate analysis as described above, were included as covariates in the multivariate analysis using the Cox hazard model. As given in Table 4 , the results showed that non-adenocarcinoma histology (HR = 2.825, 95% CI: 1.825-4.367, P < 0.001), serum CEA at recurrence ≥5.0 mg/dl (HR = 2.205, 95% CI: 1.453-3.344, P < 0.001) and no systemic chemotherapy (HR = 2.137, 95% CI: 1.304-3.247, P = 0.002) were independent prognostic factors. Figure 1B shows the PRS curves according to histological type (adenocarcinoma vs others). The 2-year PRS rates of patients with adenocarcinoma and that with others were 58.4 and 21.7%, respectively. The PRS period for patients with adenocarcinoma was also significantly longer than those with other histology (P < 0.001). Figure 2A shows the PRS curves according to the serum CEA at recurrence (<5.0 vs ≥5.0 mg/dl). The 2-year PRS rates of patients with normal CEA and elevated CEA were 50.8 and 32.6%, respectively. The PRS period for the normal CEA group was significantly longer than the elevated CEA group (P = 0.002). Figure 2B reveals the PRS curves according to post-recurrence chemotherapy (yes vs no). The 2-year PRS rates of the cases receiving chemotherapy and cases not receiving chemotherapy were 47.8 and 39.3%, respectively. The PRS period for patients who had undergone chemotherapy was significantly longer than those who had not undergone treatment (P < 0.001).
Additional prognostic analyses in the subgroup excluding cases with intrapulmonary metastasis, as initial recurrence
We also performed prognostic analyses in the subgroup excluding cases with intrapulmonary metastasis, as initial recurrence. This subgroup consisted of 56 males (62.9%) and 33 females (37.1%), with a median age of 67 years (range: 49-84 years).
Supplementary Table 2 shows the following significant predictors of PRS in univariate analysis: age at recurrence (<65 vs ≥65 years, P = 0.002), histological type (adenocarcinoma vs others, P < 0.001) and serum CEA at recurrence (<5.0 vs ≥5.0 mg/dl, P = 0.016).
Supplementary Table 3 also shows that systemic chemotherapy (P < 0.001) and radiotherapy (P < 0.001) were significant predictors of PRS. Then, we performed multivariate analysis, demonstrating that non-adenocarcinoma histology (HR = 2.289, 95% CI: 1.141-4.766, P = 0.004), serum CEA at recurrence ≥5.0 mg/dl (HR = 1.839, 95% CI: 1.059-3.195, P = 0.031), no systemic chemotherapy Table 4 ).
DISCUSSION
In the last decade, surgical outcomes for patients with NSCLC initially completely resected have improved [2, 3] . Adjuvant chemotherapy has been known to prolong survival in stage IB-III patients [8, 9] . In addition, development of new cytotoxic agents and molecular-targeted drugs, high-precision radiotherapy and advancement of diagnostic imaging may contribute to the improvement of PRS. Therefore, we performed analyses of updated PRS in patients with completely resected NSCLC to help determine which of these factors are responsible for the improved outcomes. In the current study, the PRS was 44.6% at 2 years and 25.9% at 5 years and the median PRS period was 22.5 months. At first glance, it seems that this is an improvement compared with 8.1-12.6 months reported in the literature up to 5 years ago [10] [11] [12] . However, we must be aware that the patient backgrounds of these older studies were quite different from our patient background; therefore, we should not compare survival data with each other. Moreover, the current PRS data seem much better than the survival of newly diagnosed Stage IV NSCLC patients with a median survival period of just 4 months [13] . Thus, it might be necessary for clinical trials to separate patients with recurrent NSCLC initially completely resected from patients with Stage IV NSCLC.
Previous studies have investigated the prognostic factors in patients with postoperative recurrent NSCLC only in Stage I cases [12, 14] . We should mention here that not only Stage I NSCLC developed recurrent diseases after initial complete resection. In fact, our results showed that the proportion of patients who developed recurrence of Stage II or III primary tumours was 26.8% (Table 2 ). Based on this result, we reasoned that we should make decisions on the management for recurrent disease after surgical resection regardless of primary tumour staging. Therefore, we set the current cohort to include patients with stage I-III primary disease. Furthermore, we were also interested in determining whether or not primary tumour staging and pathological factors of the primary tumour affected PRS.
The current study conducted an extensive investigation of potential risk factors for PRS in patients with NSCLC initially completely resected and it led to the identification of three independent prognostic factors, non-adenocarcinoma histology, elevated serum CEA at recurrence and no systemic chemotherapy (Table 4) . Generally, second primary lung cancer could be misdiagnosed as intrapulmonary metastasis after complete resection despite the application of the Martini and Melamedo criteria [7] . Thus, we also performed prognostic analysis in the subgroup excluding cases with intrapulmonary metastasis, as initial recurrence. The factors identified to be independent predictors of PRS following additional analysis in this subgroup were consistent with those demonstrated in the analysis of the original cohort (Tables 2-4) . These results suggested the reliability of our data analyses and diagnosis of pulmonary metastasis.
This study showed that histological type, serum CEA at recurrence and post-recurrence systemic chemotherapy were independent prognostic factors of PRS. Several researchers reported that non-adenocarcinoma histology and no systemic chemotherapy are associated with unfavourable PRS, supporting the current data [10, 11, 14] . On the other hand, histological invasive factors and pathological stage of primary tumour were not shown to be significant predictors even though it was demonstrated that histological differentiation, pathological stage, vascular invasion and serum CEA at initial surgery were independent prognostic indicators of overall survival (Supplementary Table 1 ). Shimada et al. also reported similar data that demonstrated these pathological factors predicted overall survival but not PRS, supporting our data [14] . It was suggested that the factors participating in postrecurrence treatment would have greater impact on PRS than the histopathological factors of primary tumour. The current result also demonstrated no difference of initial recurrence site (i.e. distant vs non-distant). Several researchers previously reported no significant difference of recurrence site in PRS [14, 15] , which agrees with the current study.
In recent years, not only have numerous randomized control trials established evidence for chemotherapy, but also new cytotoxic agents and molecular-targeted drugs have been introduced, and it has been recommended that decisions on treatment strategies be based on histology and gene mutation [16, 17] . This personalization and standardization of treatment for NSCLC has probably contributed to improvement in the prognosis of patients with advanced NSCLC in the last decade [2, 3, 18] . Thus, it is reasonable that systemic chemotherapy after recurrence was demonstrated to be an independent prognostic factor in this study.
Moreover, elevated serum CEA at recurrence was shown to be an independent unfavourable prognostic factor. Jin et al. demonstrated that pretreatment serum CEA was a significant predictive factor for overall survival and it was associated with response to systemic chemotherapy [19] . It was also reported that CEA reflects the number of tumour cells [20, 21] . These data could be a possible explanation for this result.
Currently, we have no evidence-based clinical guidelines for post-recurrence treatment. Generally, it is considered appropriate to apply local treatment, such as radiotherapy and surgical resection to specifically selected patients [22, 23] . Our result that showed a significant difference in PRS following radiotherapy only in the subgroup excluding cases with intrapulmonary metastasis as initial recurrence, also suggests that we would have to select patients for future prospective trials to prove the difference in PRS following local treatment. It should be noted that the number of patients who had undergone surgery for recurrent disease was very low and it could contribute to the negative result regarding surgery. To the best of our knowledge, there are few reports demonstrating EGFR-TKI to be an independent predictor of PRS. Katayama et al. recently reported that EGFR-TKI improved prognosis of patients with postoperative recurrent lung adenocarcinoma, especially those carrying a mutation in EGFR [24] . In this subset of patients, EGFR-TKI might be an independent predictor of PRS. However, the current multivariate analysis has failed to prove the prognostic significance of EGFR-TKI for PRS in patients with NSCLC initially completely resected and it was also not shown to be a prognostic indicator in the additional analysis for the subgroup excluding intrapulmonary metastasis. A possible explanation for these results might be that our subjects for PRS analysis included only 36 (26.1%) patients who had undergone EGFR-TKI administration and that 3 of them, with negative EGFFR mutation, were administered erlotinib as a second-line chemotherapy. Therefore, further analysis focusing on post-recurrence treatment with a larger sample size should be performed.
Several limitations of the current study are inherent in its design including the retrospective data collection, possibly concentrating a selection bias for post-recurrence treatment. In addition, lead time bias may be included in the current result, even though we employed a uniform follow-up plan. In addition, our study cohort was only composed of a single-centre, small-sized and entirely Japanese patient population, which consequently lacks ethnic diversity. Despite these limitations, we have clearly shown the predictors of PRS in patients with NSCLC who had initially undergone complete resection. It should be noted that three of the four factors were consistent with that of the additional analysis for the subgroup excluding intrapulmonary metastasis. Risk stratification using our data may be informative to improve clinical practice and could be useful for patient selection for prospective trials to investigate appropriate treatment strategy for recurrent NSCLC in patients with NSCLC initially completely resected.
CONCLUSIONS
In conclusion, this study demonstrated that non-adenocarcinoma histology, poor ECOG-PS at recurrence, elevated serum CEA at recurrence, no systemic chemotherapy after recurrence and no EGFR-TKI were independent unfavourable prognostic factors. Furthermore, histological invasive factors and pathological stage of the primary tumour were not demonstrated to be significant predictors of PRS. The current data can be informative for patient follow-up after complete resection and further clinical investigation may give us more information about PRS and accurate treatment strategy for recurrent NSCLC after initial complete resection.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at ICVTS online.
